1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Physician Views: What does the future hold for new EGFR targeting NSCLC therapies?

  • June 2014
  • Firstword Pharma
Report ID: 2185200


Table of Contents

Propelled via momentum from new data presented at the ASCO annual meeting, AstraZeneca's AZD-9291 and Clovis Oncology's CO-1686 look poised to advance the treatment paradigm for EGFR-positive non-small-cell lung cancer (NCSLC) patients over the next 12 to 18 months.

Both products are initially being developed for patients who have seen their disease progress after treatment with currently available targeted therapies, by selection of those EGFR-positive patients with the T790m mutation – which causes approximately half of the cases of acquired resistance to therapy with Tarceva (erlotinib; Roche), Iressa (gefitinib; AstraZeneca) and Gilotrif (afatinib; Boehringer Ingelheim).

The key question being asked post-ASCO is which product – AZD-9291 or CO-1686 – is superior? It is probably too soon to provide a definitive answer, but initial assessment of both products has focused primarily on side-effect profiles, given that in patients with the T790m-positive mutation AZD-9291 and CO-1686 have demonstrated comparable response rates.

While side effects for both products based on currently available data are treatable, a notable point of discussion around ASCO was increased risk of developing hyperglycaemia with CO-1686, which has caused some patients receiving the drug to also be treated with diabetes therapies. In addition, CO-1686 shows QTc prolongation, while AZD-9291 appears to have a worse side-effect profile in terms of rash and gastrointestinal events (thought to be due to slightly more pronounced off-target activity in hitting wild-type T790m negative) and also demonstrates more interstitial lung disease (ILD).

See Friday Five – 5 questions raised this week in pharma (ASCO edition) and ViewPoints: AstraZeneca senses chance to leapfrog Clovis in NSCLC race .

A second point under discussion is the possibility of eventual use for these two drugs as a first-line targeted therapy (i.e. instead of Tarceva, Iressa or Gilotrif). While AstraZeneca has been more cautious in this approach and has only recently announced that it will initiate a Phase III study (although conversely two-thirds of the company's peak forecast sales of $3 billion for AZD09291 are attached to first-line usage), Clovis is set to begin head-to-head studies for CO-1686 versus Tarceva in the current quarter. It is assumed that data from the TIGER1 study – a randomised Phase II/III registration study of CO-1686 versus Tarceva in newly diagnosed EGFR mutant patients (not screened for T790m-positive status – will be presented at next year's ASCO meeting.

To gain better physician insight on the potential future role of these two therapies, FirstWord is polling oncologists based in the US and EU5 with the following questions...

Based on currently available data, whether one of AZD-9291 or CO-1686 has a stronger overall clinical profile?

What is the potential opportunity for use of AZD-9291 and CO-1686 ahead of current EGFR therapies such as Tarceva based on current data?

What progression-free survival (PFS) benefit CO-1686 would have to demonstrate in the TIGER1 study to drive moderate switching into first-line targeted therapy patients?

Where in the treatment paradigm these T790m-positive targeting therapies are likely to be used most based on available data and physician enthusiasm?

Which product among the currently available EGFR inhibitors they expect to lose most market share at the expense of CO-1686 and/or AZD-9291?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.